• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Ionis Pharmaceuticals Inc.

    11/8/24 10:52:38 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IONS alert in real time by email
    SC 13G 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. _ )*

                

    Ionis Pharmaceuticals, Inc.


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    462222100


    (CUSIP Number)

    September 30, 2024


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 462222100

    1. NAMES OF REPORTING PERSONS

    Wellington Management Group LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Massachusetts

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 8,849,025
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 9,067,836
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    9,067,836
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.76%
    12. TYPE OF REPORTING PERSON

    HC


    CUSIP No. 462222100

    1. NAMES OF REPORTING PERSONS

    Wellington Group Holdings LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 8,849,025
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 9,067,836
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    9,067,836
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.76%
    12. TYPE OF REPORTING PERSON

    HC


    CUSIP No. 462222100

    1. NAMES OF REPORTING PERSONS

    Wellington Investment Advisors Holdings LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 8,849,025
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 9,067,836
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    9,067,836
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.76%
    12. TYPE OF REPORTING PERSON

    HC


    CUSIP No. 462222100

    1. NAMES OF REPORTING PERSONS

    Wellington Management Company LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 8,818,141
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 8,874,604
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,874,604
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.63%
    12. TYPE OF REPORTING PERSON

    IA

    Item 1.
    (a) Name of Issuer
    Ionis Pharmaceuticals, Inc.
    (b) Address of Issuer's Principal Executive Offices
    2855 Gazelle Court
    Carlsbad, CA 92010
    Item 2.
    (a) Name of Person Filing
    Wellington Management Group LLP
    Wellington Group Holdings LLP
    Wellington Investment Advisors Holdings LLP
    Wellington Management Company LLP
    (b) Address of Principal Business Office or, if None, Residence
    c/o Wellington Management Company LLP
    280 Congress Street
    Boston, MA 02210
    (c) Citizenship
    Wellington Management Group LLP - Massachusetts
    Wellington Group Holdings LLP - Delaware
    Wellington Investment Advisors Holdings LLP - Delaware
    Wellington Management Company LLP - Delaware
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    462222100
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E); *
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [X] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    If this statement is filed pursuant to Rule 13d-1(c), check this box [ ]
    Wellington Management Group LLP - HC
    Wellington Group Holdings LLP - HC
    Wellington Investment Advisors Holdings LLP - HC
    Wellington Management Company LLP - IA
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    See the responses to Item 9 on the attached cover pages.
    (b) Percent of Class:
    See the responses to Item 11 on the attached cover pages.
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 0
    (ii) shared power to vote or to direct the vote See the responses to Item 6 on the attached cover pages.
    (iii) sole power to dispose or to direct the disposition of 0
    (iv) shared power to dispose or to direct the disposition of See the responses to Item 8 on the attached cover pages.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows:

    Not Applicable.
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G.

    Wellington Group Holdings LLP – HC
    Wellington Investment Advisors LLP – HC
    Wellington Management Global Holdings, Ltd. - HC

    One or more of the following investment advisers (the “Wellington Investment Advisers”):

    Wellington Management Company LLP – IA
    Wellington Management Canada LLC – IA
    Wellington Management Singapore Pte Ltd – IA
    Wellington Management Hong Kong Ltd – IA
    Wellington Management International Ltd – IA
    Wellington Management Japan Pte Ltd – IA
    Wellington Management Australia Pty Ltd - IA

    The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable.
    Item 9. Notice of Dissolution of Group.

    Not Applicable.
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    By: Wellington Management Group LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: November 14,2024

    By: Wellington Group Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: November 14,2024

    By: Wellington Investment Advisors Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: November 14,2024

    By: Wellington Management Company LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: November 14,2024

    Get the next $IONS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IONS

    DatePrice TargetRatingAnalyst
    1/28/2026$95.00Overweight
    Barclays
    10/8/2025$80.00Neutral → Overweight
    Analyst
    9/26/2025$65.00Sell → Neutral
    Goldman
    9/3/2025$70.00Market Perform → Outperform
    BMO Capital Markets
    7/31/2025$62.00Equal-Weight → Overweight
    Morgan Stanley
    7/1/2025$57.00Equal Weight → Overweight
    Barclays
    4/7/2025$45.00Buy
    H.C. Wainwright
    3/31/2025$39.00Neutral
    Redburn Atlantic
    More analyst ratings

    $IONS
    SEC Filings

    View All

    SEC Form 10-K filed by Ionis Pharmaceuticals Inc.

    10-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

    2/26/26 4:25:52 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

    2/25/26 7:00:59 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Ionis Pharmaceuticals Inc.

    144 - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    2/2/26 4:22:41 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

    Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA)New Phase 1b data further illustrate potential of salanersen in SMA, as Phase 3 studies begin to evaluate this investigational drug that has the potential for high potency with once-yearly dosing CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) – will present new data and updates from its spinal muscle atrophy (SMA) research programs, including high dose nusinersen and salanersen, at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 8-11, 2026) and 5th International Scientific Congress on SMA (S

    3/5/26 7:30:00 AM ET
    $BIIB
    $IONS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting

    Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced new data to be presented for DAWNZERA™ (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), including new analyses from the Phase 3 OASIS-HAE and OASISplus studies. Results will be presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, PA. "These data add to a growing body of evidence outlining the clinical value of DAWNZERA for people living with HAE, highlighting its potential to deliver meaningful improvement in HAE attack rate and quality of life, including for those switching from another long-term prophylactic therapy," said Kenneth N

    2/27/26 7:00:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)

    – PDUFA date set for June 30, 2026 – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for olezarsen for severe hypertriglyceridemia (sHTG). The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 30, 2026. "Current standard of care therapies for sHTG provide limited benefit, leaving people vulnerable to recurrent and debilitating acute pancreatitis attacks with serious, long-term health consequences," said Brett P. Monia, Ph.D., chief executive officer, Ionis. "The FDA's Priority Review designation underscores the urgent need

    2/26/26 7:00:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Ionis Pharma with a new price target

    Barclays resumed coverage of Ionis Pharma with a rating of Overweight and set a new price target of $95.00

    1/28/26 7:17:25 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ionis Pharma upgraded by Analyst with a new price target

    Analyst upgraded Ionis Pharma from Neutral to Overweight and set a new price target of $80.00

    10/8/25 8:16:23 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ionis Pharma upgraded by Goldman with a new price target

    Goldman upgraded Ionis Pharma from Sell to Neutral and set a new price target of $65.00

    9/26/25 8:00:14 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    5/2/25 4:38:26 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hayden Michael R bought $181,079 worth of shares (5,000 units at $36.22), increasing direct ownership by 17% to 35,219 units (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    12/26/24 4:57:52 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Klein Joseph Iii exercised 16,000 shares at a strike of $40.76 and sold $1,696,181 worth of shares (21,332 units at $79.51), decreasing direct ownership by 33% to 11,014 units (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    3/5/26 6:14:23 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Loscalzo Joseph exercised 1,032 shares at a strike of $38.06 and sold $82,833 worth of shares (1,032 units at $80.26) (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    3/5/26 6:14:30 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Diaz Allene M. exercised 40,321 shares at a strike of $39.72 and sold $4,354,428 worth of shares (54,878 units at $79.35), decreasing direct ownership by 79% to 3,811 units (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    3/5/26 6:14:15 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Leadership Updates

    Live Leadership Updates

    View All

    Alltrna Announces Updates to Its Board of Directors

    Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

    7/17/24 8:00:00 AM ET
    $APRE
    $CYTK
    $EVLO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: Biological Products (No Diagnostic Substances)

    Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

    Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

    6/24/24 4:05:00 PM ET
    $CTNM
    $IONS
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals
    Medicinal Chemicals and Botanical Products

    Ionis announces the appointment of Michael Yang to Board of Directors

    CARLSBAD, Calif., Dec. 14, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors. Mr. Yang's appointment expands the total number of Ionis Board members to 10. Mr. Yang has more than 20 years of broad senior level leadership experience in biotech, pharmaceutical and medical device companies, where he launched new platforms, expanded global revenues and diversified product lines. He most recently served as President, Chief Executive Officer and B

    12/14/23 4:05:00 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Financials

    Live finance-specific insights

    View All

    Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs

    - TRYNGOLZA® generated $108 million in net product sales in 2025, the first year of launch – - Olezarsen sHTG launch preparations on track, sNDA submitted - - Exceeded 2025 financial guidance, 2026 guidance reflects commitment to independently deliver a steady cadence of innovative medicines to patients - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results and provided key updates for the fourth quarter and year ended December 31, 2025. "2025 was a defining year for Ionis, marked by the successful execution of our first two independent launches and multiple positive data readouts across our pipeline, positioning Ionis for continued success in 2

    2/25/26 7:00:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biogen Completes Acquisition of Alcyone Therapeutics

    CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery solutions, such as the ThecaFlex DRx™ drug delivery system. ThecaFlex DRx™ is an investigational implantable device designed to provide an alternative to repeat lumbar punctures in chronic intrathecal administration of medicines, which could ease both patient experience and accessibility for a broader population of people living with neurologic disorders. ThecaFlex DRx™ has been in development since 2019, with the PIERRE and PIERRE-PK clinical studies for nusinersen curren

    11/14/25 4:05:00 PM ET
    $BIIB
    $IONS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ionis reports third quarter 2025 financial results and highlights progress on key programs

    - TRYNGOLZA® generated $32 million in net product sales in the third quarter 2025 - - DAWNZERA™ (donidalorsen) launch off to encouraging start - - Olezarsen significantly reduced triglycerides and acute pancreatitis events in severe hypertriglyceridemia (sHTG) in landmark Phase 3 studies; sNDA submission on track by year-end – - Positive pivotal zilganersen results in Alexander disease position Ionis for first independent neurology launch in 2026 - - Increasing 2025 financial guidance driven by continued strength across the business – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results and provided key updates for the third quarter ended Sept

    10/29/25 7:00:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

    SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    11/14/24 8:34:57 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

    SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    11/14/24 1:28:29 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Ionis Pharmaceuticals Inc.

    SC 13G - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    11/8/24 10:52:38 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care